Publications

Selected Publications

Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer. 2009; 115:3858-67.

Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR 3rd, Sloan CE, Sax PE, Walensky RP. HIV pre-exposure prophylaxis (PrEP) in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009; 48:806-15.

Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008; 22:2025-33.

Teixeira PA, Schackman BR. Can urban methadone patients complete health utility assessments? Patient Educ Couns . 2008; 71:302-7.

Schackman BR, Teixeira PA, Weitzman G, Mushlin AI, Jacobson IM. Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? Med Decis Making. 2008; 28:233-242.

Koenig SP, Riviere C, Leger P, Severe P, Atwood S, Fitzgerald D, Pape JW, Schackman BR. The cost of antiretroviral therapy in Haiti. Cost Eff Resour Alloc 2008; 6:3.

Schackman BR, Dastur Z, Ni Q, Callahan M, Berger J, Rubin DS. Sexually active HIV patients frequently report never using condoms in audio computer-assisted self-Interviews conducted at routine clinical visits. AIDS Patient Care STDS. 2008; 22:123-129.

Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr. 2007; 46:547-554.

Schackman BR, Scott CA, Sax PE, Losina E, Wilkin TJ, McKinnon JE, Swindells S, Weinstein MC, Freedberg KA. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007; 45:1062-70.

Schackman, BR, Teixeira PA, Beeder AB. Offers of hepatitis C care do not lead to treatment. J. Urban Health 2007; 84:455-8.

Schackman, BR, Neukermans, CP, Nerette Fontain, SN, Nolte, C, Jospeph P, Pape, JW, Fitzgerald DW. Cost-effectiveness of rapid syphilis screening in prenatal HIV testing programs in Haiti. PLoS Medicine 2007;4:e183.

Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmissions, and costs. Ann Intern Med 2006;145:797-806.

Schackman BR, Merrill JO, McCarty D, Levi J, Lubinsky C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis 2006; 43:S247-53.

Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, Weinstein MC, Seage GR 3rd, Moore R, Freedberg KA. The lifetime cost of current HIV care in the United States. Med Care 2006; 44: 990-97

Gulick, RM, Ribaudo, HJ, Shikuma, CM, Lalama, C, Schackman, BR, Meyer, WA, Acosta, EP, Schouten, J, Squires, KE, Pilcher, CD, Murphy, RL, Koletar, SL, Carlson, M, Reichman, RC, Bastow, B, Klingman, KL, Kuritzkes, DR. Randomized, Double-Blinded, Multicenter Study of a Three- vs. Four-Drug Antiretroviral Regimen for the Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study – ACTG 5095). JAMA 2006; 296:769-81.

Joseph P, Schackman BR, Horowitz R, Nerette S, Verdier RI, Dorsainvil D, Theodore H, Acensio M, Henrys K, Wright P, Johnson W, Pape JW, Fitzgerald DW. The use of an educational video during informed consent in an HIV clinical trial in Haiti. J Acquir Immune Defic Syndr 2006; 42:588-591.

Mrus JM, Schackman BR, Wu AW, Freedberg KA, Tsevat J, Yi MS, Zackin R. Variations in self-ratedhealth among patients with HIV infection. Qual Life Res. 2006;15:503-14.

Schackman BR, Finkelstein R, Neukermans CP, Lewis L, Eldred L, for the Center for Adherence Support and Evaluation (CASE) team. The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS Care. 2005; 17:927-937.

Schackman BR, Freedberg KA, Goldie SJ, Weinstein MC, Swartz K. Budget impact of Medicaid Section 1115 demonstrations for early HIV treatment in Georgia and Massachusetts. Health Care Financ Rev. 2005; 26:67-80.

Stone PW, Schackman BR, Neukermans CP, Olchanski N, Greenberg D, Rosen, AP, Neumann PJ. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis. 2005; 5:383-91.

Schackman BR, Oneda K, Goldie SG. The cost-effectiveness of elective cesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. AIDS. 2004;18:1827-34.

Gulick RM, Ribaudo RJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR. Triple nucleoside analogue vs. efavirenz-containing regimens for the initial treatment of HIV-1 infection: AIDS Clinical Trials Group (ACTG) Study A5095. N Engl J Med. 2004; 350:1850--61.

Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? PharmacoEconomics 2004;22:293-300.

Schackman BR, Freedberg KA, Weinstein MC, Sax P, Zang H, Goldie SJ. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med. 2002;162:2478-2486.

Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J, Weinstein MC. A comparison of health state utilities using community and patient preference weights derived from a survey of HIV/AIDS patients.  Med Decis Making. 2002; 22:27-38.

Schackman BR, Goldie SJ, Weinstein MC, Losina E, Zhang H, Freedberg KA. Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Publ Health 2001;91:1456-63.

Back to topBack To Top